237 related articles for article (PubMed ID: 18569641)
1. Expression of T-plastin, FoxP3 and other tumor-associated markers by leukemic T-cells of cutaneous T-cell lymphoma.
Capriotti E; Vonderheid EC; Thoburn CJ; Wasik MA; Bahler DW; Hess AD
Leuk Lymphoma; 2008 Jun; 49(6):1190-201. PubMed ID: 18569641
[TBL] [Abstract][Full Text] [Related]
2. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas.
Klemke CD; Fritzsching B; Franz B; Kleinmann EV; Oberle N; Poenitz N; Sykora J; Banham AH; Roncador G; Kuhn A; Goerdt S; Krammer PH; Suri-Payer E
Leukemia; 2006 Jun; 20(6):1123-9. PubMed ID: 16557241
[TBL] [Abstract][Full Text] [Related]
3. Lack of suppressive CD4+CD25+FOXP3+ T cells in advanced stages of primary cutaneous T-cell lymphoma.
Tiemessen MM; Mitchell TJ; Hendry L; Whittaker SJ; Taams LS; John S
J Invest Dermatol; 2006 Oct; 126(10):2217-23. PubMed ID: 16741512
[TBL] [Abstract][Full Text] [Related]
4. Malignant Tregs express low molecular splice forms of FOXP3 in Sézary syndrome.
Krejsgaard T; Gjerdrum LM; Ralfkiaer E; Lauenborg B; Eriksen KW; Mathiesen AM; Bovin LF; Gniadecki R; Geisler C; Ryder LP; Zhang Q; Wasik MA; Odum N; Woetmann A
Leukemia; 2008 Dec; 22(12):2230-9. PubMed ID: 18769452
[TBL] [Abstract][Full Text] [Related]
5. Natural killer cells prevent CD28-mediated Foxp3 transcription in CD4+CD25- T lymphocytes.
Brillard E; Pallandre JR; Chalmers D; Ryffel B; Radlovic A; Seilles E; Rohrlich PS; Pivot X; Tiberghien P; Saas P; Borg C
Exp Hematol; 2007 Mar; 35(3):416-25. PubMed ID: 17309822
[TBL] [Abstract][Full Text] [Related]
6. Expression of Granulysin and FOXP3 in Cutaneous T Cell Lymphoma and Sézary Syndrome.
Shareef MM; Elgarhy LH; Wasfy Rel-S
Asian Pac J Cancer Prev; 2015; 16(13):5359-64. PubMed ID: 26225678
[TBL] [Abstract][Full Text] [Related]
7. CD164 identifies CD4
Benoit BM; Jariwala N; O'Connor G; Oetjen LK; Whelan TM; Werth A; Troxel AB; Sicard H; Zhu L; Miller C; Takeshita J; McVicar DW; Kim BS; Rook AH; Wysocka M
Arch Dermatol Res; 2017 Jan; 309(1):11-19. PubMed ID: 27766406
[TBL] [Abstract][Full Text] [Related]
8. Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumour-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis.
Melichar B; Nash MA; Lenzi R; Platsoucas CD; Freedman RS
Clin Exp Immunol; 2000 Jan; 119(1):19-27. PubMed ID: 10606960
[TBL] [Abstract][Full Text] [Related]
9. CTLA-4 and T cell activation.
Oosterwegel MA; Greenwald RJ; Mandelbrot DA; Lorsbach RB; Sharpe AH
Curr Opin Immunol; 1999 Jun; 11(3):294-300. PubMed ID: 10375557
[TBL] [Abstract][Full Text] [Related]
10. CD28/CTLA-4 receptor structure, binding stoichiometry and aggregation during T-cell activation.
Linsley PS; Ledbetter J; Peach R; Bajorath J
Res Immunol; 1995; 146(3):130-40. PubMed ID: 8525042
[No Abstract] [Full Text] [Related]
11. FOXP3+CD25- tumor cells with regulatory function in Sézary syndrome.
Heid JB; Schmidt A; Oberle N; Goerdt S; Krammer PH; Suri-Payer E; Klemke CD
J Invest Dermatol; 2009 Dec; 129(12):2875-85. PubMed ID: 19626037
[TBL] [Abstract][Full Text] [Related]
12. CD4+ and CD8+ T cells expressing FoxP3 in HIV-infected patients are phenotypically distinct and influenced by disease severity and antiretroviral therapy.
Lim A; French MA; Price P
J Acquir Immune Defic Syndr; 2009 Jul; 51(3):248-57. PubMed ID: 19363449
[TBL] [Abstract][Full Text] [Related]
13. Role of STAT3 in CD4+CD25+FOXP3+ regulatory lymphocyte generation: implications in graft-versus-host disease and antitumor immunity.
Pallandre JR; Brillard E; Créhange G; Radlovic A; Remy-Martin JP; Saas P; Rohrlich PS; Pivot X; Ling X; Tiberghien P; Borg C
J Immunol; 2007 Dec; 179(11):7593-604. PubMed ID: 18025205
[TBL] [Abstract][Full Text] [Related]
14. Inducible expression and pathophysiologic functions of T-plastin in cutaneous T-cell lymphoma.
Bégué E; Jean-Louis F; Bagot M; Jauliac S; Cayuela JM; Laroche L; Parquet N; Bachelez H; Bensussan A; Courtois G; Michel L
Blood; 2012 Jul; 120(1):143-54. PubMed ID: 22627769
[TBL] [Abstract][Full Text] [Related]
15. The prevalence of FOXP3+ regulatory T-cells in peripheral blood of patients with NSCLC.
Li L; Chao QG; Ping LZ; Xue C; Xia ZY; Qian D; Shi-ang H
Cancer Biother Radiopharm; 2009 Jun; 24(3):357-67. PubMed ID: 19538059
[TBL] [Abstract][Full Text] [Related]
16. Regulation of T-plastin expression by promoter hypomethylation in primary cutaneous T-cell lymphoma.
Jones CL; Ferreira S; McKenzie RC; Tosi I; Caesar JA; Bagot M; Whittaker SJ; Mitchell TJ
J Invest Dermatol; 2012 Aug; 132(8):2042-9. PubMed ID: 22495182
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells.
Berger CL; Tigelaar R; Cohen J; Mariwalla K; Trinh J; Wang N; Edelson RL
Blood; 2005 Feb; 105(4):1640-7. PubMed ID: 15514008
[TBL] [Abstract][Full Text] [Related]
18. Identification of tyrosine kinase, HCK, and tumor suppressor, BIN1, as potential mediators of AHI-1 oncogene in primary and transformed CTCL cells.
Kennah E; Ringrose A; Zhou LL; Esmailzadeh S; Qian H; Su MW; Zhou Y; Jiang X
Blood; 2009 May; 113(19):4646-55. PubMed ID: 19211505
[TBL] [Abstract][Full Text] [Related]
19. Functional analysis of acquired CD28 mutations identified in cutaneous T cell lymphoma.
Gmyrek GB; Pingel J; Choi J; Green JM
Cell Immunol; 2017 Sep; 319():28-34. PubMed ID: 28711152
[TBL] [Abstract][Full Text] [Related]
20. CD80 on Human T Cells Is Associated With FoxP3 Expression and Supports Treg Homeostasis.
Soskic B; Jeffery LE; Kennedy A; Gardner DH; Hou TZ; Halliday N; Williams C; Janman D; Rowshanravan B; Hirschfield GM; Sansom DM
Front Immunol; 2020; 11():577655. PubMed ID: 33488578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
